Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice.

Tam VC, Tannock IF, Massey C, Rauw J, Krzyzanowska MK.

J Clin Oncol. 2011 Aug 10;29(23):3133-9. doi: 10.1200/JCO.2010.33.3922.

PMID:
21747079
3.

Publication outcomes of phase II oncology clinical trials.

Hoeg RT, Lee JA, Mathiason MA, Rokkones K, Serck SL, Crampton KL, Emmel AE, Severson EA, Go RS.

Am J Clin Oncol. 2009 Jun;32(3):253-7. doi: 10.1097/COC.0b013e3181845544.

PMID:
19349853
4.

Factors associated with failure to publish large randomized trials presented at an oncology meeting.

Krzyzanowska MK, Pintilie M, Tannock IF.

JAMA. 2003 Jul 23;290(4):495-501.

PMID:
12876092
5.
6.

Reporting of trials presented in conference abstracts needs to be improved.

Hopewell S, Clarke M, Askie L.

J Clin Epidemiol. 2006 Jul;59(7):681-4.

PMID:
16765270
7.
8.

Presentation and subsequent publication rates of phase I oncology clinical trials.

Camacho LH, Bacik J, Cheung A, Spriggs DR.

Cancer. 2005 Oct 1;104(7):1497-504.

9.

Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.

Bedard PL, Krzyzanowska MK, Pintilie M, Tannock IF.

J Clin Oncol. 2007 Aug 10;25(23):3482-7.

PMID:
17687153
10.

Publication rate of abstracts from the annual ASTRO meeting: comparison with other organizations.

Papagikos MA, Rossi PJ, Lee WR.

J Am Coll Radiol. 2005 Jan;2(1):72-5.

PMID:
17411764
11.

Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting.

Massey PR, Wang R, Prasad V, Bates SE, Fojo T.

Oncologist. 2016 Mar;21(3):261-8. doi: 10.1634/theoncologist.2015-0516.

PMID:
26888691
12.
13.

Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: guidelines for improved reporting.

Krzyzanowska MK, Pintilie M, Brezden-Masley C, Dent R, Tannock IF.

J Clin Oncol. 2004 May 15;22(10):1993-9.

PMID:
15143092
14.

Improving the quality of abstract reporting for phase I cancer trials.

Strevel EL, Chau NG, Pond GR, Murgo AJ, Ivy PS, Siu LL.

Clin Cancer Res. 2008 Mar 15;14(6):1782-7. doi: 10.1158/1078-0432.CCR-07-4886.

15.
16.
17.

American Society of Clinical Oncology 41st annual meeting.

Dillman RO.

Expert Opin Biol Ther. 2005 Aug;5(8):1117-27. Review.

PMID:
16050788
18.

Abstracts presented at the American Urological Association Annual Meeting: determinants of subsequent peer reviewed publication.

Hoag CC, Elterman DS, Macneily AE.

J Urol. 2006 Dec;176(6 Pt 1):2624-9; discussion 2629.

PMID:
17085176
19.

Hot topics and landmark studies from the 43rd annual meeting of the American Society of Clinical Oncology.

Puglisi F, Aprile G, Fasola G.

Anticancer Drugs. 2008 Feb;19(2):221-33. doi: 10.1097/CAD.0b013e3282f2c938.

PMID:
18176120
20.

Presentation of nonfinal results of randomized controlled trials at major oncology meetings.

Booth CM, Le MaƮtre A, Ding K, Farn K, Fralick M, Phillips C, Cescon DW, Meyer RM.

J Clin Oncol. 2009 Aug 20;27(24):3938-44. doi: 10.1200/JCO.2008.18.8771.

PMID:
19620490
Items per page

Supplemental Content

Support Center